Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 5:13:1520772.
doi: 10.3389/fpubh.2025.1520772. eCollection 2025.

Tearing down inequalities in the healthcare system across Europe: the BEACON project

Chrysanthi Koukoutzeli  1 , Giulia Ferraris  2 , Veronica Coppini  2 , Maria Vittoria Ferrari  2 , Elisa Fragale  2 , Dario Trapani  1   3 , Ida Minchella  1 , Roberto Grasso  2   3 , Giuseppe Curigliano  1   3 , Gabriella Pravettoni  2   3
Affiliations
Review

Tearing down inequalities in the healthcare system across Europe: the BEACON project

Chrysanthi Koukoutzeli et al. Front Public Health. .

Abstract

Equity in healthcare remains a pressing issue in cancer care across the European Union. Although numerous European initiatives address prevention, early diagnosis, and treatment, significant disparities in access to innovative cancer therapies persist. Time-to-reimbursement for new anticancer drugs varies widely between member states, depending on national health policies, economic capacity, and healthcare infrastructure. These differences particularly affect countries in Central and Eastern Europe, where delays in reimbursement, limited access to clinical trials, and restricted availability of specialized care contribute to worse outcomes. This narrative review examines how disparities in reimbursement timelines and access to new cancer therapies may affect factors such as early detection, specialized treatment availability, clinical trial participation, and socioeconomic status. The discussion is framed within the BEACON project, a European Union-funded initiative under the EU4Health programme. BEACON brings together patients, healthcare providers, researchers, and policymakers to create a cross-border network for quality-assured diagnosis and treatment. Through its multilingual digital platform, the project fosters collaboration, supports health literacy, and enhances access to innovative cancer therapies, aiming to reduce inequities regardless of geographic or socioeconomic background.

Keywords: Europe; cancer; health disparities; new therapies; new treatment; socioeconomic status; survival; time to reimbursement.

PubMed Disclaimer

Conflict of interest statement

GC received honoraria for speaker’s engagement: Roche, Seagen, Astra Zeneca, Daichii Sankyo, Novartis, Lilly, Pfizer, Roche, BMS, MSD; Menarini, Gilead. Honoraria for providing consultancy: Roche, Seagen, Novartis, Lilly, Pfizer, Menarini, Astra Zeneca, Daichii Sankyo, Gilead; Honoraria for participating in Advisory Board: Seagen, Novartis, Lilly, Pfizer, Menarini, Astra Zeneca, Daichii Sankyo, Gilead; Ellipsis; Institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Sero-no, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, Medimmune. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Stakeholder-centered functionalities of the BEACON App. The BEACON app offers tailored features for healthcare providers, patients, policymakers, and researchers to improve access to cancer care and reduce disparities across the European Union.
Figure 2
Figure 2
The BEACON framework within the cancer care continuum. The BEACON framework integrates key phases of cancer care screening, diagnosis, treatment, and accessibility with systemic determinants such as time to reimbursement, real word evidence and PROMs, socioeconomic factors, clinical trials, access to innovative therapies, and digital health literacy, aiming to reduce disparities and enhance equity across the European oncology landscape.
See this image and copyright information in PMC

References

    1. Aristotle L. Nichomachean ethics. Trans. Ostwald M. Upper Saddle River, NJ: Prentice Hall (1999)
    1. Ward A. Justice as Economics in Aristotle’s Nicomachean Ethics. Can Polit Sci Rev. (2010) 4:1–11.
    1. Santucci C, Mignozzi S, Malvezzi M, Boffetta P, Collatuzzo G, Levi F, et al. European cancer mortality predictions for the year 2024 with focus on colorectal cancer. Ann Oncol. (2024) 35:308–16. doi: 10.1016/j.annonc.2023.12.003, PMID: - DOI - PubMed
    1. Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. (2021) 11:808. doi: 10.3390/jpm11080808 - DOI - PMC - PubMed
    1. ECPC . Improving cancer care through broader access to quality biomarker testing policy recommendations unlocking the potential of precision medicine in Europe. (2021).

LinkOut - more resources